North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and the University of Zurich were able to demonstrate that the levels of medication used are often too low. As a result, patients remained contagious with the dangerous disease for longer than necessary.

More than 4,000 people worldwide die from tuberculosis every day. This means the disease tops the list of the most common causes of death that result from a single pathogen. The people who are most affected are those also suffering from an immune deficiency, such as an HIV infection. However, the high rate of mortality isn't unavoidable: Tuberculosis can be cured if the relevant drugs are used correctly.

But this is precisely where the problem lies. The most important medications for treating tuberculosis - in Switzerland, too - date back to the 1960s: Treatment is lengthy, involves several pills, and comes with numerous side effects. People thus often discontinue their treatment, which means that patients continue to suffer from the disease and also pass it on to others. In addition, the optimal dose of tuberculosis drugs has also not yet been determined.

Concentration of medication in the blood

Led by Prof. Jan Fehr, researchers at UZH and the UniversityHospital Zurich have now joined forces with a team of researchers from a partner university in Kampala, Uganda, to tackle this question. Over a two and half year period, the researchers repeatedly measured the concentration of tuberculosis medication in the blood of 268 study patients suffering from pulmonary tuberculosis as well as an HIV infection. At the same time, they carried out further tests including tests to detect the pathogen in the sputum. Patients took their medication in accordance with the currently valid dosage guidelines of the World Health Organization (WHO).

Contagious for a longer period of time

"We were able to show that the concentrations of the two principal tuberculosis drugs, namely isoniazid and rifampicin, in the blood were very clearly below the internationally targeted levels," explains Prof. Jan Fehr. These lower blood concentrations mean that tuberculosis patients cough up tuberculosis bacteria for a longer period of time compared to patients with higher levels of medication in their blood. "These patients with lower levels of isoniazid and rifampicin thus also remain contagious for longer."

Blood levels have to be measured regularly

This in turn has far-reaching global consequences. The WHO aims to cut the rate of tuberculosis deaths by 90 percent by 2030. However, this will only succeed if the global epidemic can be controlled and infections don't spread any further. To achieve this, we must think about how routine checks of the levels of the major tuberculosis drugs can be implemented and how to increase the dosage if the levels are too low. Relevant studies need to be carried out, and should be based on the SOUTH study, which was the first study worldwide to investigate this topic in great depth.

Christine Sekaggya-Wiltshire, Amrei von Braun, Mohammed Lamorde, Bruno Ledergerber, Allan Buzibye, Lars Henning, Joseph Musaazi, Ursula Gutteck, Paolo Denti, Miné de Kock Alexander Jetter, Pauline Byakika-Kibwika, Nadia Eberhard, Joshua Matovu, Moses Joloba, Daniel Muller, Yukari C Manabe, Moses R Kamya, Natascia Corti, Andrew Kambugu, Barbara Castelnuovo, Jan S Fehr.
Delayed Sputum Conversion in TB-HIV Co-Infected Patients with Low Isoniazid and Rifampicin Concentrations.
Clinical Infectious Diseases, ciy179, doi: 10.1093/cid/ciy179.

Most Popular Now

Delivering insulin in a pill

Given the choice of taking a pill or injecting oneself with a needle, most of us would opt to regulate a chronic health condition by swallowing a pill. But for millions o...

Probiotics can protect the skeletons of older wome…

For the first time in the world, researchers at the University of Gothenburg, Sweden, have demonstrated that probiotics, dietary supplements with health-promoting bacteri...

Alzheimer's breakthrough: Brain metals that may dr…

Alzheimer's disease could be better treated, thanks to a breakthrough discovery of the properties of the metals in the brain involved in the progression of the neurodegen...

Can aspirin treat Alzheimer's?

A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer's disease pathology and protect memory, according to neurological r...

FDA approves first drug comprised of an active ing…

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms o...

In mice, stem cells seem to work in fighting obesi…

Obesity is an increasing global health problem associated with several comorbidities and a high risk of mortality. A wide spectrum of interventions has been proposed for ...

FDA takes steps to foster greater efficiency in bi…

Today, the agency withdrew the draft guidance, "Statistical Approaches to Evaluate Analytical Similarity," issued in September 2017. The draft guidance, if finalized as w...

Research shows how a moderate dose of alcohol prot…

For at least 20 years, research has shown that for many people, moderate consumption of alcohol can protect the heart, but the reason for this is poorly understood. A stu...

Some existing anti-cancer drugs may act in part by…

Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti...

'Kiss of death' cancer

It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy. Triple negativ...

Novartis Clear about Psoriasis survey data highlig…

Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1]. The publica...

Poliovirus therapy for recurrent glioblastoma has …

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, wit...